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Adnectins are targeted biologics derived from the
tenth type III domain of human fibronectin (10Fn3),
a member of the immunoglobulin superfamily.
Target-specific binders are selected from libraries
generated by diversifying the three 10Fn3 loops that
are analogous to the complementarity determining
regions of antibodies. The crystal structures of two
Adnectins were determined, each in complex with
its therapeutic target, EGFR or IL-23. Both Adnectins
bind different epitopes than those bound by known
monoclonal antibodies. Molecular modeling sug-
gests that some of these epitopes might not be
accessible to antibodies because of the size and
concave shape of the antibody combining site. In
addition to interactions from the Adnectin diversified
loops, residues from the N terminus and/or the
b strands interact with the target proteins in both
complexes. Alanine-scanning mutagenesis con-
firmed the calculated binding energies of these
b strand interactions, indicating that these nonloop
residues can expand the available binding footprint.
INTRODUCTION
Adnectins (a trademark of Adnexus, a Bristol-Myers Squibb R&D
Company) are a class of targeted biologics derived from the
tenth type III domain (10Fn3) of the abundant extracellular
protein human fibronectin (Dickinson et al., 1994; Koide et al.,
1998; Xu et al., 2002; Getmanova et al., 2006) (Figure 1).
10Fn3-based variants can be rapidly developed to bind proteins
or therapeutic targets of interest with high affinities (Xu et al.,
2002; Hackel et al., 2008;Wojcik et al., 2010). Thus, their function
is analogous to therapeutic monoclonal antibodies.
The first Adnectin tested in a clinical trial, CT-322, targets
vascular endothelial growth factor receptor-2 (VEGFR-2).
Preclinical (Mamluk et al., 2010) and phase I studies on CT-322
(Bloom and Calabro, 2009; Molckovsky and Siu, 2008; Tolcher
et al., 2011) demonstrated that it was well tolerated and
produced pharmacological effects expected from the inhibition
of the VEGFR-2 pathway.Structure 20, 25The 10Fn3 domain is a member of the immunoglobulin (Ig)
superfamily and contains a ‘‘beta sandwich’’ protein fold that
bears striking resemblance to an antibody domain (Dickinson
et al., 1994; Main et al., 1992) (Figure 1D). This structural
homology led to the concept that the 10Fn3 domain could be
modified to mimic an antibody variable domain and bind mole-
cules other than its natural target integrin. In fact, 10Fn3 contains
three loops that are analogously located to the complementarity
determining regions (CDRs) of an antibody variable domain (Fig-
ure 1). The first example of a modified 10Fn3 domain bound ubiq-
uitin. It was selected by phage display from a library with five
residues randomized in each of two of the three CDR-analogous
loops (Koide et al., 1998). This accomplishment led to the selec-
tion of a number of 10Fn3-based variants that bound other
targets, including therapeutically relevant targets, such as
TNF-a and VEGFR-2 (Xu et al., 2002; Getmanova et al., 2006;
Parker et al., 2005).
The large database of antibody/target structures has provided
insights into how antibodies interact with a wide range of
binding partners. In contrast, the understanding of the molecular
interactions that create the affinity of 10Fn3-based variants for
their targets is based on more limited structural information.
The structures of 10Fn3-based variants (also known as mono-
bodies) bound to maltose binding protein (MBP) yield some
insights into these molecular interactions, but because these
structures required creating a fusion protein between the MBP
and the 10Fn3-based domain, the interactions may not be
completely representative of the interactions that happen
without tethering (Gilbreth et al., 2008). Similarly, an affinity
clamp technique used to increase affinity of a protein for a target
peptide by fusing the protein to an 10Fn3-based domain that
also interacts with the target peptide (Huang et al., 2009) yielded
structural information on engineered 10Fn3 domains interacting
with targets, but not an independent 10Fn3-based domain inter-
action. Two more relevant examples involve complexes of
10Fn3-based domain with Abl SH2 domain and SUMO. The
former used residues from all three diversified loops as well as
some residues from the 10Fn3 scaffold to interact with the Abl
SH2 domain (Wojcik et al., 2010). The latter showed interactions
with only the FG loop supplemented by scaffold residues
(Gilbreth et al., 2011).
Adnectins that specifically bound epidermal growth factor
receptor (EGFR) or interleukin 23 (IL-23), two therapeutically
validated targets, were generated using the mRNA display tech-
nique described previously (Xu et al., 2002). These Adnectins9–269, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 259
Figure 1. Comparison of Antibody, VH Fragment, and Adnectin
Showing Relative Size of the Molecules
(A–C) Cartoon diagrams of IgG1 (PDB ID 1IGT) (A); VHH (1F2X) with the CDRs
marked 1, 2, and 3 (B); and an Adnectin (C), with the diversified loops marked
BC, DE, and FG.
(D) Superposition of an Adnectin and VHH shows that the positions of BC, DE,
and FG loops are similar to those CDRs 1, 2, and 3.
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Expanded Binding Footprint of Adnectin Complexesinhibit the binding of their target to the target’s cognate receptor
or ligand and also block intracellular signaling of the target/ligand
interactions in cell-based assays. A representative Adnectin that
blocked each target was selected for cocrystallization with its
target to identify the nature of the contacts.
Blocking EGFR signaling is a validated strategy for cancer
therapy, as demonstrated by numerous FDA-approved drugs
that target EGFR, including cetuximab, panitumumab, erlotinib,
and lapatinib (for a review see Flynn et al., 2009). The anti-
EGFR Adnectin described here binds to a site on EGFR distinct
from the epitopes of approved monoclonal antibodies, but it
nonetheless displays similar activity in that both Adnectin and
antibodies block EGF binding to the receptor and thus block
intracellular signaling.
IL-23 is required for the survival and expansion of proinflam-
matory Th17 cells and as such is an important therapeutic target
for the treatment of inflammatory diseases (Awasthi and Kuch-
roo, 2009). IL-23 is a heterodimer consisting of a 40 kDa subunit
(p40) that is shared with IL-12 and a unique 19 kDa subunit (p19),
and signals through a heterodimeric receptor (IL-12RB1 and
IL-23R). A monoclonal antibody, ustekinumab, which binds to
p40, blocks both IL-12 and IL-23 signaling and has been
approved by the FDA for the treatment of psoriasis, an inflamma-
tory disease linked to inappropriate Th17 cell responses (Elliott
et al., 2009; Krueger et al., 2007; Papp et al., 2008: Leonardi
et al., 2008; Reddy et al., 2007). The anti-IL-23 Adnectin
described in this article binds to a site that partially consists of
the p19 subunit resulting in specificity for IL-23 alone, and thus
targeting the Th17 proinflammatory effects while sparing the
IL-12-mediated Th1 cellular functions affected by ustekinumab.
Analysis of the structures of EGFR- and IL-23-binding Adnec-
tins yields multiple insights into the molecular interactions
between 10Fn3-based variants and their targets. Many of the
diversified loop residues contact the target. More interestingly,
not all the residues in the three diversified loops (Figure 1C)
were at or near the 10Fn3-based domain/target interface.
Conversely, several wild-type residues outside of the diversified260 Structure 20, 259–269, February 8, 2012 ª2012 Elsevier Ltd All rloops interact with the target protein. Main chain conformations
of the two target-binding Adnectins and wild-type 10Fn3 were
similar, but conformations of the three diversified loops and the
N terminus were different from wild-type to facilitate binding to
the respective target protein’s surface.
On the basis of the structures of Adnectin complexes with
EGFR or IL-23, Adnectins provide a binding surface area that
is similar in size to that of Fvs. In addition, the smaller size of
Adnectins and the convex shape of their binding surface allow
Adnectins to bind to surfaces in their targets that would be steri-
cally inaccessible to Fvs. This suggests that Adnectins are
a viable alternative to antibodies andmay access therapeutically
relevant epitopes not accessible to Fvs.
RESULTS
Identification of EGFR and IL-23 Antagonistic Adnectins
Adnectins that bind to and block activity of either EGFR (Adnec-
tin 1) or IL-23 (Adnectin 2) were identified using the biochemical
selection technique of mRNA display in which a protein is cova-
lently attached to its coding nucleic acid sequences (Xu et al.,
2002; Getmanova et al., 2006; Roberts and Szostak, 1997) (Fig-
ure 4A; Supplemental Experimental Procedures available
online). Adnectin 1 binds the EGFR ectodomain Fc fusion with
a 2 nM Kd and inhibits EGF-induced EGFR phosphorylation in
H292 cells with an IC50 of50 nM. Adnectin 2 binds immobilized
IL-23 with a 2 nM Kd and competes with the IL-23/IL-23R inter-
action with an IC50 of 1 nM in a biochemical receptor binding
competition assay. Adnectin 1 was cocrystallized with EGFR,
and Adnectin 2 was cocrystallized with IL-23 to determine the
structural basis of these activities.
Overview of the Structure of the EGFR/Adnectin 1
Complex
EGFR is a remarkably flexiblemolecule with differing interactions
among the four domains. EGFR structures deposited in the PDB
(1IVO, 1NQL, and 1YY9) show that domains I and III are relatively
rigid, whereas parts of domains II and IV may adopt multiple
conformations that orient domain III differently with respect to
domain I (Ogiso et al., 2002; Ferguson et al., 2003; Li et al.,
2005). The structure of EGFR in the EGFR/Adnectin 1 complex
most closely resembles 1NQL, which is a complex of EGFR
with EGF at low pH and is considered to be an inactive form of
the receptor. However, superimposition of domain I of the two
complexes leads to centers of domain III of the two complexes
being separated by 25 A˚, showing once again the remarkable
flexibility of EGFR. The Adnectin binds to EGFR domain I (Fig-
ure 2A) overlapping the binding site of EGF on EGFR domain I
in either its active (1IVO) or inactive (1NQL) forms and, therefore,
sterically hinders EGF binding (Figure 2D; Figure S1D). This site
is a radically different site from antibodies that bind to EGFR on
domain III. Cetuximab (1YY9) and necitumumab (3B2V) bind to
essentially the same site (Figure 2A), but are oriented differently,
and matuzamab (3C09) binds to a distinct site on domain III (Li
et al., 2005, 2008; Schmiedel et al., 2008).
The Adnectin reported here has an insertion of five residues in
the FG loop. To retain a consistent numbering scheme, residues
inserted in the FG loop were given insertion letters (Figure 4A)
analogous to that devised for immunoglobulins by Kabat et al.ights reserved
Figure 2. Binding of Adnectin 1 to EGFR
(A) The EGFR is represented as a gray surface and is
shown bound to Adnectin 1 on domain I and the Fv portion
of cetuximab on domain III (PDB 1YY9; Li et al., 2005).
Adnectin and cetuximab are shown as cartoons with
b strands (red), and nonrepetitive secondary structure
(cyan).
(B) Residues of Adnectin 1 involved in contacts with EGFR.
The Adnectin backbone is shown as a cartoon with the
following color scheme: b strands (red), nonrepetitive
secondary structure (orange), and diversified loops
(magenta). Residues involved in contacts from the diver-
sified loops are shown with magenta carbon atoms.
Residues involved in contacts from the remainder of the
Adnectin are shown with black carbon atoms and black
regions on the secondary structure cartoon. Note the
sequential stretch in the D strand that contacts EGFR.
(C) Interaction between Adnectin and EGFR domain I.
Adnectin is in magenta and EGFR cartoon is in cyan. The
interacting surface on EGFR shows the stricter definition
of contacting residues in orange and the relaxed definition
of buried residues in yellow.
(D) Overlap of Adnectin 1 and EGF contacting surfaces on
EGFR domain I is shown. Adnectin 1 (cyan) and EGF
(blue) are represented as cartoons. The unique contacting
surfaces and overlapping surface are shown as Adnectin 1
(yellow), EGF (red), and for both (magenta).
(E) b-strand-like interactions between EGFR residues
15–18 and Adnectin 1 residues 76–79 with N.O=C
hydrogen bonds formed between Q16 N and D77 O,
K79 N and Q16 O, and L17 N and K79 O, and a side-chain
hydrogen bond between T16 OG1 and D77 OD1.
See also Figure S1.
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Expanded Binding Footprint of Adnectin Complexes(1991) and similar to that used by Gilbreth et al. (2008) for the
BC loop.
Specific Interactions of Adnectin 1 with EGFR
The interaction between Adnectin 1 and EGFR domain I results in
520 A˚2 on the Adnectin and590 A˚2 on EGFR domain I that are
buried by the interaction (Figure 2C; Figure S1C). The size of
these interacting surfaces is toward the smaller end typical of
antibody/protein antigen interfaces (Sheriff, 1993). They are
also smaller than those seen for other 10Fn3-based variants
(Table 1; Gilbreth et al., 2008, 2011; Huang et al., 2009; Wojcik
et al., 2010), but affinities for Adnectin 1 and the antibodies
surveyed are of the same order of magnitude. The relatively small
size of the interaction is due to the convex surface on EGFR con-
sisting of loops connecting the two b sheets at one edge of
a b sandwich domain interacting with the convex surface of
the Adnectin (Figure 2C). Nevertheless, the Sc statistic (Law-
rence andColman, 1993), which is ameasure of the complemen-
tarity of the binding surfaces, for this complex is 0.71, falling
toward the lower end of the range of protease/protease inhibitors
(0.71–0.76) and oligomeric interfaces (0.70–0.74) and above the
range observed for antibody/antigen complexes (0.66–0.68)
(Lawrence and Colman, 1993) and slightly above the mean of
10Fn3-based domain/protein complexes (Table 1). This suggests
that, although the surface of interaction is relatively small for the
Adnectin 1/EGFR complex, it is a more complementary fit than
seen with antibodies and their antigens.
The principal interactions of the Adnectin occur through the
FG loop (175 A˚2 of buried surface), the D strand (175 A˚2),Structure 20, 25the DE loop (70 A˚2), the C strand (50 A˚2), and the BC loop
(40 A˚2) (Figure 2C; Figure S1C). The residues from the Adnectin
with van derWaals radii dependent contact (Sheriff, 1993; Sheriff
et al., 1987a) to EGFR are as follows: BC loop, Gln30; C strand,
Tyr31; D strand, Glu47, Phe48, Thr49, Val50, and Pro51; DE
loop, Val54; and FG loop, Asp77, His78, Lys79, Ala79C, and
His81 (Figures 2B, 2C, and 2E; Figures S1C–S1E). The remark-
able feature of this interface is the extensive interactions
between the wild-type backbone sequence of the D strand in
the Adnectin and the EGFR—it contributes as much surface
area and as many residues as does the diversified FG loop
interaction. Aromatic residues (His, Phe, and Tyr) contribute
1/4 of the surface area (120 A˚2) of the overall Adnectin inter-
action surface, but only one tyrosine (31) is involved, which is
part of the Adnectin scaffold and whose side chain lies parallel
to the rather flat EGFR surface. The N terminus and most of
the BC and DE loops are on the distal side of the Adnectin
from the EGFR and are thus not involved in the interaction.
A b-sheet-like interaction occurs between Adnectin 1 and
the N-terminal region of EGFR, which displays 3 N.O=C
hydrogen bonds and one side-chain-to-side-chain hydrogen
bond (Figure 2E).
Alanine-Scanning Mutagenesis of EGFR/Adnectin 1
Single-site alanine mutants (Wells, 1991) were made for 30 of the
101 residues of the Adnectin. All residues in the BC, DE, and FG
loops that were diversified as part of the selection process were
included, as well as any other residue that was in contact (see
above) with EGFR (Table 2; Table S1). Mutation of the following9–269, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 261
Table 1. Comparison of Buried Surface Area, Contacts, and Surface Complementarity for 10Fn3-Based Domain Complexes
PDB ID Protein Pair
Target Protein 10Fn3-Based Variant Type of Contacts
Surface
Complementarity
Area,
A˚2
No. of
Residues
No. of
Atoms
Area,
A˚2
No. of
Residues
No. of
Atoms
No. of
Hydrogen
Bonds
No. of
Salt
Links
No. of
van der Waals
Interactions
2OCF ERa 900 22 47 870 17 51 6 2 77 0.66
3CSB MBP 650 16 59 600 14 51 7 0 121 0.70
3CSG MBP 750 15 56 680 15 53 11 1 125 0.64
3K2M SH2 AD 570 16 47 580 10 48 11 2 105 0.72
BC 570 13 48 530 12 49 11 3 109 0.76
3QHT ySUMO AC 600 13 48 560 12 43 8 0 87 0.71
BD 610 12 46 570 13 35 9 0 74 0.67
3QWQ EGFR 590 14 39 520 13 41 8 0 75 0.71
3QWR IL-23 1370 38 97 1320 29 99 16 4 197 0.73
In cases of multiple complexes per asymmetric unit, all are tabulated. The letters indicates chain names in the pairs. Area was calculated by themethod
of Connolly (1983) and rounded to the nearest 10 A˚2. The number of residues and number of atoms in contact were calculated by the method of Sheriff
et al., 1987a and Sheriff (1993). The numbers of atompairwise hydrogen bonds and van derWaals interactions were calculated by themethod of Sheriff
et al. (1987a) and Sheriff (1993). The number of salt links is tabulated on a per residue basis. Surface complementarity was calculated by the method of
Lawrence and Colman (1993).
Proteins: ERa, estrogen receptor a; MBP, maltose binding protein; SH2, Src homology 2 from Abelson kinase; ySUMO, yeast small ubiquitin-related
modifier.
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Expanded Binding Footprint of Adnectin Complexesresidues led to significantly diminished binding: Tyr 29, Gln 30,
Tyr 31, Gly 52, Val 54, Asp 77, Lys 79, His 81, and Tyr 83. Surpris-
ingly, Tyr 29, Gly 52, and Tyr 83 do not directly interact with
EGFR. These can be explained on the basis of structural interac-
tions within the Adnectin. Tyr29 side chain packs in the interior of
the BC loop and against the F strand and mutation to Ala would
be expected to disrupt the BC loop. Because Gly52 is part of
a Pro-Gly-Pro turn, changing Gly to Ala might have disrupted
this structural element. Tyr83 side chain forms an edge-to-face
interaction with His81 side chain and a hydrogen bond with
Glu85 side chain. His81 side chain, in turn, interacts with EGFR
Thr15, and it is likely the diminished activity due to mutating
Tyr83/Ala is due to its helping maintain the position of His81.
Prior to the alanine-scanning mutagenesis, the energetics of
the interaction were calculated on a per-residue basis. These
calculations correctly identified Gln 30, Tyr 31, and Asp 77 as
being important to the interaction, but also identified Pro 51 as
being important, although mutation to Ala did not affect binding
(Table 2; Table S1). The remaining residues that interacted with
EGFR and were identified by alanine scanning—Val 54, Lys 79,
and His 81—all showed changes in the correct direction (Table
2), but the magnitude of the change did not reach the threshold
considered significant (3 kcal/mol).
Mutagenesis of Contact Residues of EGFR/Adnectin 1
Six residues—Tyr31, Glu47, Thr49, Pro51, Thr58, and Ala79C—
were targeted for additional mutation studies on the basis of
interaction energy predictions calculated frommodels to explore
the possibility that mutations might increase the binding affinity
of Adnectin 1. Most mutations, which were typically attempts
to create either hydrogen-bond or charged interactions, did
not substantially change the affinity compared to the parent
(Table 3; Table S2). However, the three mutations to residue 49
to increase the van der Waals interactions by converting a Thr
to a Val, Ile, or Tyr, increased the affinity of the Adnectin by262 Structure 20, 259–269, February 8, 2012 ª2012 Elsevier Ltd All r8–40-fold (Table 3; Table S2). Because the side chain of Thr49
is not in contact with EGFR, presumably mutation to a larger
side chain (Ile or Tyr) creates additional hydrophobic contacts
with residues from EGFR located in the surface depression
next to Thr 49 (Figure 2C). In the case of Thr49/Val, the substi-
tution of a methyl for the hydroxyl, which is pointing toward
a hydrophobic environment, presumably accounts for the
increased affinity.
Overview of the Structure of the IL-23/Adnectin 2
Complex
IL-23 is a two subunit protein consisting of a p40 subunit that is
shared with IL-12 and a p19 subunit that is distinct from the p35
subunit of IL-12. The p40 subunit consists of three Ig-like seven-
stranded b sheet domains, whereas the p19 consists of a four-
helix bundle. Adnectin 2 binds at the junction of the p40 and
p19 subunits, making considerable interactions with both
subunits, including domains 2 and 3 of the p40 subunit (Figures
3A and 3C–3E; Figures S2C–S2E). Despite the interactions with
p40, Adnectin 2 does not inhibit IL-12 binding or signaling (data
not shown). Moreover, although the diversified loops are toward
the center of the interface, interactions extend along the
b strands away from the diversified loops and include the CD
loop on the opposite end of the molecule. This concave site is
likely inaccessible to Fvs, which are much larger, consisting of
two domains from separate subunits and six hypervariable
loops. In fact, the Adnectin-binding site is dramatically different
from that of the one known antibody complex for IL-23 (PDB
3D85), which binds only to the p19 subunit (Beyer et al., 2008)
(Figure 3A).
Specific Interactions of Adnectin 2 with IL-23
The interaction between the Adnectin and IL-23 is quite large,
burying 1320 A˚2 on the Adnectin surface and 1370 A˚2 on
the IL-23 surface (Figure 3C; Figure S2C). This amount of buriedights reserved
Table 2. EGFR Alanine Scan
Mutation
Secondary
Structural
Element
Kd
(nM)
Activity
(Parent/
Mutant)
pEGFR
IC50 (Parent/
Mutant)
DInteraction
Energy
(kcal/mol)
Parent 1.8 1 1 0
D23/A BC loop 2.4 0.7 0.3 0
S24/A BC loop 1.3 1.4 0.7 0
G25/A BC loop 2.0 0.9 0.3 0
R26/A BC loop 2.0 0.9 0.8 0
G27/A BC loop 1.1 1.6 1.4 0
S28/A BC loop 1.5 1.2 0.5 0
Y29/A BC loop 14 0.1 0.02 0
Q30/A BC loop >50 <0.04 NT 3
Y31/A C strand ND NT 5
F48/A D strand 3.9 0.5 0.1 1
T49/A D strand 1.5 1.2 0.1 1
V50/A D strand 3.4 0.5 0.1 1
P51/A D strand 1.8 1 NT 3
G52/A DE loop 14 0.1 0.04 0
P53/A DE loop 2.8 0.6 0.3 1
V54/A DE loop 17 0.1 0.03 2
H55/A DE loop 3.0 0.6 0.6 0
D77/A FG loop ND ND 6
H78/A FG loop 5.5 0.3 0.1 2
K79/A FG loop 17 0.1 0.0 1
P79A/A FG loop 4.0 0.4 0.1 0
H79B/A FG loop 3.9 0.5 0.1 0
H79D/A FG loop 2.8 0.6 0.2 1
G79E/A FG loop 4.4 0.4 0.1 0
P80/A FG loop 4.2 0.4 0.1 0
H81/A FG loop 10 0.2 0.0 1
T82/A FG loop 6.1 0.3 0.1 0
Y83/A FG loop ND ND 0
H84/A FG loop 2.1 0.8 0.4 0
E85/A FG loop 4.9 0.4 0.05 0
pEGFR IC50 is the inhibitory concentration at which phosphorylation of
EGFR is inhibited 50%. In the DInteraction Energy column, bold indicates
what are expected to be significant losses of interaction energy.
See also Table S1.
ND, not detected; NT, not tested.
Table 3. EGFR Mutants that Attempt to Improve Binding
Mutation
Secondary
Structural
Element
Kd
(nM)
Activity
(Parent/
Mutant)
pEGFR
IC50 (Parent/
Mutant)
DInteraction
Energy
(kcal/mol)
Parent 1.8 1 1
Y31/F BC loop 2.0 0.9 NT 2
Y31/S BC loop 0.70 2.5 NT 5
Y31/L BC loop ND ND 2
E47/R D strand 0.83 2.1 NT 4
E47/K D strand 0.9 2.0 NT 6
E47/D D strand 0.78 2.3 NT 0
T49/I D strand 0.05 37 4.2 0
T49/V D strand 0.14 12 3.1 1
T49/Y D strand 0.21 8.4 1.0 3
P51/T D strand ND NT 1
P51/L D strand 1.5 1.2 NT 1
T58/Q E strand 2.2 0.8 0.3 0
T58/E E strand 1.3 1.3 0.7 9
T58/D E strand 1.1 1.7 1.4 7
A79C/L FG loop 4.0 0.4 NT 3
A79C/N FG loop 2.3 0.8 NT 4
A79C/Y FG loop 3.2 0.5 NT 8
A79C/R FG loop 4.3 0.4 NT 11
A79C/E FG loop 2.7 0.7 NT 8
pEGFR IC50 is the inhibitory concentration at which phosphorylation of
EGFR is inhibited 50%. In the DInteraction Energy column, bold indicates
what are expected to be significant losses of interaction energy, and italic
indicates what are expected to significant gains of interaction energy.
See also Table S2.
ND, not detected; NT, not tested.
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Expanded Binding Footprint of Adnectin Complexessurface area is larger than most antibody/antigen interactions
and, presumably, reflects the concave nature of the binding
site on IL-23. The buried surface is also much larger than that
for any other 10Fn3-based domain complex (Table 1). Despite
the large interacting surface, the affinity of Adnectin 2 for IL-23
is the same order of magnitude as the antibodies for their protein
antigens. The Sc statistic for this complex is 0.73, which
suggests that it is more complementary than the antibody/
antigen complexes surveyed by Lawrence and Colman (1993)
and second largest of the 10Fn3-based domain/protein
complexes (Table 1).
The principal interactions occur through the FG (610 A˚2) and
BC (380 A˚2) loops, but most segments of secondary structureStructure 20, 25have at least some surface area buried by the interaction (Figures
3C; Figure S2C). The following residues from the Adnectin
are found to contact IL-23: N-terminal region, Pro5, Arg6, and
Asp7; BC loop, Glu23, His24, Asp25, Tyr26, Pro27, Tyr28, and
Arg30; C strand, Tyr31 and Arg33; CD loop, Gly40, Asn42,
and Val45; F strand, Tyr73 and Val75; and FG loop, Thr76,
Ser77, Ser78, Tyr79, Lys80, Tyr81, Asp82, Met83, Gln84,
Tyr85, and Pro87 (Figures 3B–3E; Figures S2C–S2E). Four points
stand out from this list. First, the number of interacting residues is
large and they come from many of the b strands and loops.
Second, no contacts occur between the diversified DE loop
and IL-23. Third, a large number (seven) of tyrosine residues
are involved in the interaction. The frequent occurrence of tyro-
sine has been observed for antibodies, VH fragments, and
10Fn3-based variants interacting with antigens (Padlan, 1990;
Mian et al., 1991; Kossiakoff and Koide, 2008; Koide and Sidhu,
2009), and is presumably due to the relatively low loss of entropy
due to relatively few dihedral angles that become immobilized
compared to large surface area that tyrosine residues are able
to contribute, which amounts to a total of 450 A˚2 in this case.
Moreover, several of these tyrosines (20, 79, 81, and 85) appear
to fit into crevices in the IL-23 surface (Figures 3D and 3E).
Fourth, a large number (11) of nondiversified residues are
involved in direct interactions with IL-23. Residues in this fourth
category include two of the seven Tyr residues and residues at9–269, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 263
Figure 3. Binding of Adnectin 2 to IL-23
(A) The IL-23 is represented as a gray surface and is shown
bound to Adnectin 2 at the interface between the p40 and
p19 subunits, and the Fv portion of 7G10 is shown bound
to p19 subunit (PDB 3D85; Beyer et al., 2008). Adnectin
and 7G10 are shown as cartoons with the same color
coding as Figure 2A.
(B) Adnectin 2 residues involved in contacts with IL-23.
Adnectins 1 (Figure 2B) and 2 are oriented identically to
allow comparison of the differing shapes by inspection.
Color coding is the same as in Figure 2B. In Adnectin 2, the
following regions make contact with IL-23: the N-terminal
region, the C strand, the CD loop, the E strand, and the F
strand.
(C) Interaction between Adnectin and IL-23, with the color
coding of the surface and the Adnectin the same as Fig-
ure 2C. The p40 domain (chain A) is shown in a lighter
cyan, and the p19 domain (chain B) is shown in a darker
cyan.
(D) A view of the Adnectin 2/IL-23 interaction involving only
the diversified loops and N-terminal region. Same color
coding as in (C).
(E) A view showing only residues 76–85 of the FG loop of
Adnectin 2 bound to IL-23.
See also Figure S2.
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Expanded Binding Footprint of Adnectin Complexesthe N terminus. Although electron density is interpretable for only
part of the N terminus, it is clear that the N terminus does not
point in the direction of the BC, DE, and FG loops as it does in
the wild-type 10Fn3, but rather reverses direction and points
toward the opposite end of the molecule.
Mutagenesis of Contact Residues of IL-23/Adnectin 2
Four amino acids—Tyr28, Tyr73, Tyr81, and Pro87—were
mutated to alanine to demonstrate that energetically important
residues could be predicted. This proved to be the case for
Tyr28, Tyr81, and Pro87 but not for Tyr73, which had little
effect when mutated to alanine (Table 4). Tyr28 is located in
the center of the BC loop and forms significant contacts with
amino acids that are at the terminus of the IL-23 p19 domain
A-helix (e.g., edge-to-face interactions with Trp26 and
His29). Similarly, Tyr81 which is located in the center of the
FG loop, has significant contacts with the IL-23 p40 subunit
(e.g., Ser204). Pro87, which is located at the C terminus of
the FG loop, may be required for retaining the FG loop confor-
mation and contacts residues Gly100 and Pro101 from the
IL-23 p40 subunit. Although Tyr73 is predicted to contribute
6 kcal (Table S3) to the interaction, this is less than half
that predicted for Tyr28 (16 kcal) and Tyr81 (13 kcal) (Table
S3). In the minimized structure, the Tyr73 side chain forms
a hydrogen bond with IL-23 p40 subunit Lys99 carbonyl
oxygen, but the Tyr73/Ala mutant shows that it is not a key
energetic residue.264 Structure 20, 259–269, February 8, 2012 ª2012 Elsevier Ltd All rights reservedComparison of the Structures of
Adnectin 1 and Adnectin 2 with 10Fn3
Structural comparisons show that the wild-type
molecule (10Fn3; 1FNF residues 1416–1509) has
a topology very similar to that of Adnectin 1 and
Adnectin 2 when bound to their target mole-
cules (Figure 4; Figure S3), including an excel-lent overlay of the core b sheet and two of the three loops (AB
and DE) distal from those that were diversified for selection
(Figure 4A; Figure S3A). The BC and DE loops of Adnectin 1
and Adnectin 2 are identical in length to the wild-type. In these
structures, the short DE loop shows minimal variation, whereas
the BC loop shows more variation when compared to the
10Fn3 structure. Lys52 side chain in the DE loop of Adnectin 2
is close enough to the BC loop that it may be involved in stabi-
lizing the displaced position of that loop compared to wild-type
10Fn3. The largest variations are in the FG loop, where, in the
1FNF crystal structure, the native RGD motif is involved in
a crystal contact and that contact is likely responsible for its
orientation in that structure. The FG loop of Adnectin 1 is 5 resi-
dues longer than that of either 10Fn3 or Adnectin 2 and the F and
G strands are extended. However, those residues involved in the
extended b strands are shown as tubes rather than arrows in Fig-
ure 4 to emphasize the diversified residues. In Adnectin 2, the FG
loop adopts yet a different conformation when bound to IL-23.
Finally, it should be noted that the N terminus is flexible in Adnec-
tins. In 10Fn3, the position is dictated by the link to 9Fn3. In
Adnectin 1, the N terminus has a relatively similar conformation
since it does not interact with EGFR. On the other hand, the N
terminus of Adnectin 2 is folded away compared to the other
two N termini, presumably to avoid collision with IL-23. Thus,
these structures show that Adnectin loops may adopt conforma-
tions distinct from wild-type depending upon the protein/protein
interaction.
Table 4. IL-23 IC50
Mutation
Secondary
Structural
Element
IC50
(nM)
Activity
(Parent/Mutant)
DInteraction
Energy
(kcal/mol)
Parent 1.0 1
Y28/A BC loop 13 0.08 10
Y73/A F strand 0.65 1.5 5
Y81/A FG loop 35 0.03 7
P87/A FG loop 8.3 0.1 2
T35/N C strand 1.7 0.6 0
T35/Q C strand 1.0 1 2
T35/E C strand 0.6 1.7 6
T35/D C strand 49 0.02 7
V45/N D strand 0.54 1.8 1
V45/Q D strand 0.34 2.9 0
V45/E D strand 0.51 1.9 6
V45/D D strand 0.83 1.2 6
Y73/N F strand 1.2 0.8 2
Y73/Q F strand 0.26 3.8 3
Y73/R F strand 1.2 0.8 2
V75/Y F strand 2.2 0.4 1
V75/Q F strand 2.3 0.4 0
V75/K F strand 5.7 0.2 1
In the DInteraction Energy column, bold indicates what are expected to
be significant losses of interaction energy, and italic indicates what are
expected to significant gains of interaction energy.
See also Table S4.
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Space group, unit cell parameters and data collection statistics
for both complexes are listed in Table 5. Initial electron density
for the diversified loops, which were excluded from the molec-
ular replacement model, is shown for the final model for both
complexes in Figure 5.
DISCUSSION
The three-dimensional structures of antibody/protein antigen
complexes have been studied for over 20 years (Amit et al.,
1986; Colman et al., 1987; Sheriff et al., 1987b; Padlan et al.,
1989). Antibody combining sites are made up of the CDRs on
VL and VH domains and they tend to be slightly concave. Fabs
and Fvs thus tend to bind to protein surfaces that are slightly
convex. However, as shown for camelid VH domains, single
domain binding proteins often present convex binding surfaces
with protuberances and are able to bind to surfaces such as
enzyme active sites that are less accessible to typical Fvs (Des-
myter et al., 1996; De Genst et al., 2006). This behavior has also
been seen in a 10Fn3-based domain (Gilbreth et al., 2011).
However, in all of these cases, essentially a single loop inserts
into a cleft. In the case of Adnectin 2, the entire ‘‘nose cone’’
(i.e., the N-terminal region and BC and FG loops) of the domain
inserts into a concave surface made by the junction of the p19
and p40 domains of IL-23. Interestingly, although the N-terminal
region and the BC and FG loops insert into a canyon on the IL-23
surface, the DE loop does not interact with IL-23. In contrast, theStructure 20, 25Fab of the antibody 7G10 (PDB ID 3D85) binds to a convex
surface of the p19 subunit of IL-23 (Figure 2A). Thus, as postu-
lated, Adnectins may bind to surfaces that are likely less acces-
sible to Fvs.
In contrast to most camelid VH domains (Desmyter et al.,
1996; De Genst et al., 2006) and the structures of other 10Fn3-
based variants (Gilbreth et al., 2008, 2011; Huang et al., 2009;
Wojcik et al., 2010), Adnectin 1 binds to a somewhat convex
surface on EGFR, although the most convex part is covered by
the extended FG loop. The interaction between Adnectin 1 and
EGFR is rather narrow, which is consistent with two slightly
convex surfaces interacting.
According to mutagenesis studies, only a fraction of structur-
ally defined interface residues contribute substantially to the
energetics of protein/protein interactions (Cunningham and
Wells, 1989, 1993; Clackson and Wells, 1995). Similarly, a rela-
tively small number of EGFR/Adnectin 1 complex interface
residues (6 of 11) had a significant effect on binding when
experimentally mutated to alanine. The combination of alanine-
scanning mutagenesis and energetics calculations defined the
energetic binding site or paratope of Adnectin 1 as Gln30 from
the BC loop, Tyr31 from the C strand, Val54 from the DE loop,
and Asp77, Lys79, and His81 from the FG loop.
The libraries for the diversified loops for both Adnectins con-
sisted of a codon mix with 10% tyrosine. In Adnectin 1, this led
to only two tyrosine residues (Tyr 29 and Tyr 83) among the 26
diversified residues (8%) with neither involved in interactions
with EGFR, although both are crucial for maintaining the shape
of their respective loops. In contrast, in Adnectin 2, five tyrosine
residues are among the 21 diversified residues (24%) and all
are involved in interactions with IL-23. This contrast shows that
the amino acid content in the binding loops can be driven by
selection against target epitopes in spite of the codon bias of
the starting library. In fact, one might speculate that the rather
flat, slightly concave surface of the EGFR epitope is not particu-
larly conducive to accommodating interactions with tyrosine
side chains, whereas the highly concave and uneven surface
of IL-23 is extremely conducive to interactions with tyrosine
side chains.
In Gilbreth et al. (2011), the authorsmake general observations
that10Fn3-based variants appear to be good crystallization
chaperones and that the scaffold of 10Fn3-based variants plays
a role in their recognition of targets. Koide (2009) has previously
championed the use of VHH domains as crystallization chaper-
ones, and the results of Gilbreth et al. (2011) suggest that
10Fn3-based variants may be equally competent. Our experi-
ence in attempting to crystallize target proteins with Adnectins
has also yielded a very high rate of success, typically greater
than 80%.With respect to the use of the scaffold in target recog-
nition, in this article we have shown two more 10Fn3-based
variants, Adnectins 1 and 2, that use residues in the scaffold
as part of the recognition surface.
In summary, features of 10Fn3-based variants complexes,
many of which have also been noted by Koide and co-workers
(Gilbreth et al., 2008, 2011; Huang et al., 2009; Wojcik et al.,
2010), are as follows. First, despite the large number of residues
involved in the interaction, residues in the three diversified loops
on the Adnectin are not required to be in direct contact with the
target (IL-23/Adnectin 2 complex). Second, N terminus and the9–269, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 265
Figure 4. Comparison of Adnectin 1 and
Adnectin 2 with 10Fn3
(A) Amino acid sequences of the two Adnectins
versus the parent 10Fn3 domain. The parts of BC,
DE, and FG loops that were diversified are un-
derlined in the figure, encompassing residues
23–29, 52–55, and 77–86, respectively.
(B and C) Two orthogonal views superimposed on
PDB 1FNF residues 1416–1509. Color code: 1FNF
(blue), Adnectin 1 (red), and Adnectin 2 (cyan).
Note the excellent superposition of the core
b strands and the AB and EF loops. The DE loop,
which is quite short, shows little variation in these
structures. The BC loop shows modest variation.
In contrast, the FG loop shows dramatic variation
in position even between the equal-length
Adnectin 2 and 10Fn3 loops. In Adnectin 1, the F
and G b strands extend farther into the diversified
region; however, to highlight the diversified region
those residues were drawn as nonrepetitive
secondary structures. Although the N termini of
the 10Fn3 and Adnectin 1 are similar, that of
Adnectin 2 differs considerably.
See also Figure S3.
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Expanded Binding Footprint of Adnectin Complexesdiversified loops (particularly the FG loop) may adopt conforma-
tions other than those seen in the wild-type 10Fn3 structure.
Presumably, the loops are somewhat flexible, but only certain
conformations are capable of productively interacting with
a target, which is what is seen in the complexes. Third, Adnec-
tins, by virtue of their small size and convex shape, may enable
binding to surfaces that are inaccessible to Fvs, for example,
the concave junction between the p40 and p19 domains of
IL-23. Finally, although Adnectins are less than half the size of
Fvs, they are fully capable of burying as much surface with their
targets. All of these capabilities suggest that Adnectins may
prove to be a very successful platform for developing protein
therapeutics that may increase the diversity of druggable target
sites.
EXPERIMENTAL PROCEDURES
Purification and Activity Assays
Expression and Purification of anti-IL-23 and anti-EGFR Adnectins was analo-
gous to that described previously (Mamluk et al., 2010). Inhibition of EGFR and
IL-23 activities by these proteins was measured by competition ELISA binding
assays of interleukin-23 and native IL-23 receptor (IL-23R). Nunc Maxisorp
plates (Thermo Fisher Scientific, Denmark) were coated overnight with 50 ml
of recombinant human IL-23R-Fc (R&D Systems, Minneapolis, MN), 4 mg/ml
in PBS, at 4C. Plates were washed with PBS containing 0.05% w/v Tween-
20 using an automated plate washer (Biotek, VT). OptEIA buffer (BD Biosci-
ence, CA) was used as blocking agent and assay diluent. Adnectin dilutions
ranging from 28 pM to 200 nM were preincubated with 1 nM IL-23 for an266 Structure 20, 259–269, February 8, 2012 ª2012 Elsevier Ltd All rights reservedhour prior to transfer to blocked IL-23R-Fc-coated
plates. After a 30-min incubation, bound IL-23 was
detected via anti-IL-23 (GeneTex, CA) and
anti-mouse-HRP (R&D Systems, MN) followed by
TMB (3,30,5,50-tetramethylbenzidine) (BD Biosci-
ence, CA) addition. The percentage of inhibition
was calculated by using a known IL-23 Adnectin
neutralizing standard to define 100% inhibition
and a nonbinding Adnectin standard as a negative
control. IC50 values were generated from the aver-age of four runswith an in-house curve fitting application. Adnectin inhibition of
phosphorylation of EGFR on tyrosine 1068 was determined using an H292 cell
in vitro ELISA assay as described elsewhere (Emanuel et al., 2011).
Surface Plasmon Resonance Determination of Adnectin
Binding Constants
The Kd for Adnectin 2was determined by surface plasmon resonance (SPR) on
a Biacore T100 instrument (GE Healthcare, Piscataway, NJ), by injecting a
concentration series of the Adnectin over three densities of immobilized
human IL-23 in single cycle kinetics mode without regeneration of the surface.
The KD for Adnectin 1 binding to recombinant EGFR-Fc (containing amino
acids 25 to 645 of human EGFR ectodomain, R&D Systems) captured on
mouse anti-human IgG antibody (GE Healthcare) was assessed by SPR.
Anti-human IgG was immobilized on flow cells 1–4 of CM5 sensor chips
according to the manufacturer’s instructions to an average of 7500–10000
RU. All kinetic measurements were conducted in HBS-P (10 mM HEPES,
150 mM NaCl, 0.05% Surfactant P20) at 37C with 3 MMgCl2 as regeneration
solution. Kinetics of Adnectin-EGFR association were monitored for 250 s
followed by dissociation for up to 3000 s with Adnectin concentrations of
0.78-100 nM. Kinetic parameters for both were calculated using Biacore
T100 software.
Expression and Purification of Human IL-23
A bi-cistronic construct for expressing the p40 and p19 subunits of IL-23 was
created by cloning the p19 subunit into pFastBac Dual vector (Invitrogen)
under control of the PpH promoter and the p40 subunit using hp19-pFastBac
Dual under control of the Pp10 promoter. Human IL-23 was expressed in Sf9
cells, which secreted the IL-23 protein into the growth media. The medium
containing IL-23 was concentrated and buffer exchanged into either PBS or
Tris-buffered saline using tangential flow filtration. Active IL-23 was affinity
Table 5. Data Collection and Refinement Statistics
EGFR/Adnectin 1 IL-23/Adnectin 2
Data collection
Space group P212121 I212121
Cell dimensions
a, b, c (A˚) 68.0, 72.1, 262.0 77.7 A˚, 91.7, 225.8
a, b, g () 90, 90, 90 90, 90, 90
Resolution (A˚) 50–2.75
(2.85–2.75)
42.47–3.25
(3.37–3.25)
Rsym 0.069 (0.552) 0.096 (0.320)
I / sI 23.1 (3.1) 7.6 (3.2)
Completeness (%) 99.6 (100.0) 98.0 (99.5)
Redundancy 4.8 (5.0) 4.0 (3.9)
Refinement
Resolution (A˚) 49.47–2.75 42.48–3.25
No. reflections 34,224 12,815
Rwork / Rfree 0.202 / 0.246 0.234 / 0.264
No. atoms 5610 4040
B-factors (A˚2) 65 101
Protein (A˚2) 63 101
Carbohydrate (A˚2) 100 115
Water (A˚2) 43 68
Rmsds
Bond lengths (A˚) 0.010 0.010
Bond angles () 1.4 1.4
Ramachandran plot statisticsa
Most favored (%) 84.5 85.8
Additional allowed (%) 13.7 11.3
Disallowed (%) 0.8 1.1
One crystal was used for each complex.
a As defined by Laskowski et al. (1993).
Figure 5. Electron Density for Diversified Loops
Stereo views of the initial electron density with the final model of the diversified
loops, which were not included in the initial model, of Adnectin 1 (A) and
Adnectin 2 (B).
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Expanded Binding Footprint of Adnectin Complexespurified from this concentrate by means of a novel Adnectin affinity column
consisting of purified anti-IL-23 Adnectin protein covalently linked via primary
amine coupling to CNBr-activated Sepharose 4 Fast Flow resin (GE Health-
care) according to the manufacturer’s instructions and employing an overnight
linkage incubation at 4C. Concentrated buffer exchanged media was passed
through a column packedwith this affinity resin at a linear flow rate of 20 cm/hr.
The column bed was washed with five column volumes of buffer alone. Highly
purified IL-23 was eluted with 0.1 M acetate (pH 4.0) and 1.0 M NaCl, and the
eluate was immediately pH neutralized with 1/10 volume Tris HCl (pH 8.0). The
sample was further purified using a preparative scale Superdex 200 size exclu-
sion chromatography (SEC) column equilibrated and run in HBS buffer.Purification of EGFR
Human EGFR (residues 1–642) with a C-terminal His-tag was expressed in Sf9
cells. The secreted media containing human EGFR was concentrated and
buffer exchanged into 25 mM Tris-HCl (pH 8.0), 250 mM NaCl, and 5% (v/v)
glycerol using tangential flow filtration. The human EGFR was purified by Ni-
NTA chromatography followed by size exclusion chromatography on a Super-
dex 200 column (GE Healthcare), and fractions corresponding to the EGFR
monomer were combined.Preparation andPurification of EGFR/Adnectin 1 and IL-23/Adnectin
2 Complexes
Human EGFR was mixed with anti-EGFR Adnectin at a 1:6 molar ratio and
incubated on ice for 2 hr. A 1:1 EGFR: Adenectin-1 complex was purified using
SEC on a Superdex 200 column equilibrated and run in 25 mMHEPES (pH 7.5)Structure 20, 25and 200 mM NaCl. Purified complex was concentrated using a Vivaspin 5 kDa
cutoff concentrator to 20 mg/ml.
Human IL-23/Adnectin 2 complex was purified analogously with the
following modifications using IL-23 purified as described above: IL-23 and
Adnectin-2 were mixed at a 1:3 molar ratio and were incubated overnight at
4C; the final complex was concentrated to 12 mg/ml.
Crystallization of Protein Complexes
EGFR/Adnectin-1 complex was crystallized at 20C using a hanging drop
vapor diffusion method by mixing 1 ml of protein complex with 1 ml of reservoir
solution containing 60% Tacsimate (Hampton Research, Aliso Viejo, CA).
IL-23/Adnectin-2 complex with a one-fold molar excess of Adnectin-2 was
crystallized in the same manner at 20C, but used 1 M tri-sodium citrate,
0.2 M NaCl, and 0.1 M Tris (pH 7.0) for Adnectin 2. The crystal quality of
IL-23/Adnectin-2 complex was improved using crystal seeding.
Data Collection and Processing
Data for the EGFR/Adnectin 1 complex were collected at beamline 21ID-G at
LS-CAT at the Advanced Photon Source at Argonne National Laboratory. The
wavelength used was 0.979 A˚, and the detector was a Rayonix MX-300. Data
were indexed, integrated, and scaled with HKL2000 (Otwinowski and Minor,
1997). Data for IL-23/Adnectin 2 were collected at beamline 17ID at IMCA-
CAT at the Advanced Photon Source at Argonne National Laboratory. The
wavelength used was 1.0 A˚, and the detector was a MAR 165 CCD. Data
were indexed, integrated, and scaled with D*TREK (Pflugrath, 1999). Space
group, unit cell parameters, and data collection statistics for both data sets
are listed in Table 5.
Molecular Replacement
Amodel for the Adnectins was derived from PDB 1FNF by deleting the BC, EF,
and FG loops. The model for EGFR was based on domains of 1NQL. The9–269, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 267
Structure
Expanded Binding Footprint of Adnectin Complexesmodel for IL-23 was a structure determined in a different crystal form from
those published in the literature (3DUH and 3D87). PHASER (McCoy et al.,
2007) was used for molecular replacement. When PHASER failed to find the
Adnectin in the IL-23/Adnectin 2 complex, a six-dimensional search using
the AMoRe translation function was successfully used (Sheriff et al., 1999;
Navaza and Vernoslova, 1995; CCP4, 1994).
Model Building, Refinement, and Analysis
COOT (Emsley et al., 2010) was used for model building. Refinement was
carried out with autoBUSTER (BUSTER, version 2.13.0. Cambridge, UK:
Global Phasing). Refinement statistics are listed in Table 5. Initial electron
density for the diversified loops with the final model is shown in Figure 5.
Display graphics were produced with PyMOL (version 1.4; Schro¨dinger,
LLC, 2009). Buried surface area was calculated with the program MS (Con-
nolly, 1983) using a 1.7 A˚ probe sphere, contacting residues were enumerated
as defined elsewhere (Sheriff, 1993; Sheriff et al., 1987a), and both use
extended atomic radii as defined by Gelin and Karplus (1979).
Estimates of Residue Free Energies and Interaction Energies
The atomic models of the complexes were optimized using the Protein Prep-
aration Wizard workflow in MAESTRO 9.0.211 (Schro¨dinger, LLC, 2009). The
estimate of Gibbs free energy was calculated as described previously
(Novotny et al., 1989; Krystek et al., 1993) and implemented in a python script
using MAESTRO (Maestro, version 9.0; Schro¨dinger, LLC, 2009).
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Coordinates and structure amplitudes have been deposited in the RCSB
Protein Data Bank under ID codes 3QWQ (EGFR/Adnectin 1) and 3QWR
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